Cannabis for Inflammatory Bowel Disease

  title={Cannabis for Inflammatory Bowel Disease},
  author={Timna Naftali and Refael Mechulam and Lihi Bar Lev and Fred Meir Konikoff},
  journal={Digestive Diseases},
  pages={468 - 474}
The marijuana plant Cannabis sativa has been used for centuries as a treatment for a variety of ailments. It contains over 60 different cannabinoid compounds. Studies have revealed that the endocannabinoid system is involved in almost all major immune events. Cannabinoids may, therefore, be beneficial in inflammatory disorders. In murine colitis, cannabinoids decrease histologic and microscopic inflammation. In humans, cannabis has been used to treat a plethora of gastrointestinal problems… 
Therapeutic Use of Cannabis in Inflammatory Bowel Disease.
Large, double-blind, randomized, placebo-controlled trials using serial inflammatory markers, biopsy findings, and endoscopic disease severity to demonstrate objective improvement in IBD are necessary before cannabis can be empirically accepted and recommended as an IBD treatment option.
Cannabis in Gastrointestinal Disorders
Clinical evidence supporting the therapeutic role of cannabis in nausea and vomiting related to chemotherapy and cachexia of AIDS is reviewed and studies on the use of cannabis for other GI disorders are limited and sparse.
Cannabis and the Gastrointestinal Tract.
  • L. Cohen, M. Neuman
  • Medicine, Biology
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2020
With limited evidence of efficacy and safety of Cannabis in IBD, IBS, and NAFLD, randomized controlled studies are required to examine its therapeutic efficacy.
Role of cannabis in inflammatory bowel diseases
Cannabis is now being considered as a potential drug for inflammatory GI conditions, particularly IBD, because of its spreading legalization in the United States and other countries and the growing trend in its use.
Insights into the role of cannabis in the management of inflammatory bowel disease
Cannabis may be effective in the symptomatic management of IBD and physicians need to be aware of its safety and efficacy in order to better counsel patients.
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines.
High THC Oil in Ulcerative Colitis: A Case Report
It is suggested that THC could be the most effective cannabinoid for the treatment of IBS-related symptoms and the oromucosal route the better way of administration.
Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review
Limited research evidence regarding the therapeutic use of cannabinoids for IBD warrants future investigation via RCTs; cannabis provides some benefits to IBD patients by improving their general well-being perceptions, Harvey-Bradshaw Index, Mayo scores, and minimizing their clinical complications.
[Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].
Cannabis may be useful for symptom relief in Crohn's disease such as pain, nausea, and loss of appetite, however, studies with high methodological quality, sufficient sample size, and study duration are mandatory to determine potential therapeutic effects and risks of cannabis in gastroenterology.
Phytotherapies in inflammatory bowel disease
Herbal therapy results for management of IBD by various mechanisms including leukotriene B4 inhibition, antioxidant activity, immune system regulation of nuclear factor-kappa B, as well as antiplatelet activity are favorable, and no unfortunate events have been yet reported.


Cannabis use amongst patients with inflammatory bowel disease
Cannabis use is common amongst patients with IBD for symptom relief, particularly amongst those with a history of abdominal surgery, chronic abdominal pain and/or a low quality of life index; the therapeutic benefits of cannabinoid derivatives in IBD may warrant further exploration.
Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.
Treatment of Crohn's disease with cannabis: an observational study.
The results indicate that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity index and in the need for other drugs and surgery.
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
Cannabidiol, a likely safe compound, prevents experimental colitis in mice and reduces colon injury and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration.
Cannabinoids and gastrointestinal motility: animal and human studies.
Modulation of the gut endogenous cannabinoid system may provide a useful therapeutic target for disorders of gastrointestinal motility.
Cannabinoids in Clinical Practice
Cannabis is frequently used by patients with multiple sclerosis for muscle spasm and pain, and in an experimental model of MS low doses of cannabinoids alleviated tremor, and an examination of psychiatric hospital admissions found no evidence of psychosis, however, it may exacerbate existing symptoms.
Cannabinoids and the gut: new developments and emerging concepts.
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice
The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
Adverse effects of medical cannabinoids: a systematic review
Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.